Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-cycloserine + CBT + NRT for Smoking Cessation
NCT01842334Phase 2
Key facts
- Status
- Terminated
- Start
- Apr 2013
- Primary completion
- Aug 2017
- Countries
- 1
- Sponsor
- McLean Hospital
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Drugs
- d-cycloserine
- Conditions
- nicotine dependence
01
Overview
Phase 2, randomised, double-blind trial in nicotine dependence comparing D-cycloserine with Placebo (2 arms). Primary endpoint: Change From Baseline in Cigarette Smoking in Treatment Seeking Nicotine Dependent Outpatients at Week 10. Started Apr 2013; status: terminated.
02
Design
2 arms- Study design
- RandomizedDouble-blind
D-cycloserine
250 mg D-cycloserine + CBT + NRT
Placebo
Placebo + CBT + NRT
03
Endpoints
Primary
Change From Baseline in Cigarette Smoking in Treatment Seeking Nicotine Dependent Outpatients
Beyond the preview
Go deeper on NCT01842334.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01842334.